Description
The abstract mentions recent progress bringing Aβ and tau research together in a new paradigm but doesn’t explain the mechanistic details of how membrane trafficking connects these pathways. Understanding this connection is critical for developing unified therapeutic approaches targeting both hallmarks of AD.
Gap type: unexplained_observation Source paper: Membrane trafficking pathways in Alzheimer’s disease. (None, None, PMID:22269004)
Resolution criteria
Resolved when an evidence artifact establishes the mechanistic link between Aβ toxicity and tau pathology through membrane trafficking, with one of: (1) systematic perturbation of membrane trafficking genes (RNAi or CRISPR screen) in neurons co-exposed to oligomeric Aβ and phosphorylated tau, identifying >=10 genes whose disruption selectively blocks the synergistic toxicity (>=40% rescue of neuronal viability) or selectively enhances it; (2) live-cell imaging of endosomal/lysosomal trafficking dynamics (Rab5, Rab7, LAMP1 reporters) in neurons with combined Aβ and tau pathology, showing specific trafficking step defects (e.g., late endosomal maturation arrest, autophagosome-lysosome fusion failure) that are rescued by overexpression of the deficient trafficking component; (3) proteomic mapping of Aβ-tau-membrane trafficking protein interactions (BioID or AP-MS) in AD brain tissue or neuronal cultures, identifying >=5 shared pathway components (e.g., APP, BACE1, GSK3β, CDK5, Rab proteins) whose perturbation disrupts both Aβ processing and tau phosphorylation.